Myriad Genetics | MYGN - Cash And Equivalent



Myriad Genetics reported $91.8M in Cash and Equivalent for its fiscal quarter ending in March of 2025.


Cash And Equivalent Change Date
Agilent USD 1.54B 49M Jul/2025
Becton, Dickinson and Co. USD 735M 68M Jun/2025
Bio-Rad Laboratories USD 369.3M 152.1M Jun/2025
Bruker USD 92M 92.2M Jun/2025
Danaher USD 2.96B 964M Jun/2025
Exact Sciences USD 657.1M 650.98M Jun/2025
Hologic USD 1.74B 305.7M Jun/2025
Illumina USD 934M 179M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Mettler Toledo International USD 61.82M 2.47M Jun/2025
Myriad Genetics USD 91.8M 10.6M Mar/2025
Quest Diagnostics USD 319M 131M Jun/2025
Quidel USD 151.7M 24.6M Jun/2025
Repligen USD 708.86M 11.63M Jun/2025
Revvity USD 991.85M 145.77M Jun/2025
Standard Biotools USD 158.62M 8.11M Jun/2025
Thermo Fisher Scientific USD 4.58B 442M Jun/2025
Veracyte USD 219.5M 33.38M Jun/2025
Waters USD 367.22M 15.66M Jun/2025